^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Fallopian Tube Cancer

    1d
    A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary (clinicaltrials.gov)
    P1/2, N=14, Terminated, Avenge Bio, Inc | Trial completion date: Aug 2026 --> Apr 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Apr 2024; Sponsor Decision to close study
    Trial completion date • Trial termination • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    AVB-001
    2d
    Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (clinicaltrials.gov)
    P3, N=448, Recruiting, Mural Oncology, Inc | Active, not recruiting --> Recruiting | Trial completion date: Dec 2026 --> May 2027 | Trial primary completion date: Dec 2025 --> May 2026
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • nemvaleukin alfa (ALKS 4230)
    6d
    The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma. (PubMed, Gynecol Oncol)
    These data demonstrate an abnormal karyometric signature in STICs that may extend beyond the STIC, potentially providing an opportunity for early detection of fallopian tube neoplasia.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset)
    6d
    Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (clinicaltrials.gov)
    P1, N=43, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting | N=21 --> 43
    Enrollment open • Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cometriq (cabozantinib capsule)
    7d
    A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=47, Terminated, Sumitomo Pharma America, Inc. | Phase classification: P1b/2 --> P1/2 | Completed --> Terminated; Sponsor's decision to terminate development of the program.
    Phase classification • Trial termination • Combination therapy • Checkpoint inhibition • Metastases
    |
    MSI (Microsatellite instability) • HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    MSI-H/dMMR • HLA-A*02 • HLA-A*24
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • adegramotide/nelatimotide (DSP-7888)
    7d
    A Study of Sovilnesib in Subjects With Ovarian Cancer (clinicaltrials.gov)
    P1, N=120, Recruiting, Volastra Therapeutics, Inc. | Not yet recruiting --> Recruiting | Phase classification: P1b --> P1
    Enrollment open • Phase classification • Metastases
    |
    sovilnesib (AMG 650)
    9d
    REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 (clinicaltrials.gov)
    P2/3, N=600, Recruiting, Sutro Biopharma, Inc. | Phase classification: P2 --> P2/3 | N=140 --> 600
    Phase classification • Enrollment change
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression • FOLR1 positive
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)
    10d
    Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076) (clinicaltrials.gov)
    P3, N=186, Recruiting, Genelux Corporation | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial primary completion date
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pegylated liposomal doxorubicin • olvimulogene nanivacirepvec (GL-ONC1)
    10d
    NCI-2018-01550: Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 5 | Trial primary completion date: Mar 2024 --> Dec 2023
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab)
    13d
    Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2026
    Trial completion date • Trial primary completion date • Surgery • Metastases
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    TP53 mutation • TP53 expression
    |
    adavosertib (AZD1775)
    13d
    MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=46, Terminated, University of Pennsylvania | N=18 --> 46 | Trial completion date: Oct 2038 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Oct 2038 --> Mar 2024; This study was halted prematurely due to recruitment barriers
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    cyclophosphamide
    15d
    The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer (clinicaltrials.gov)
    P=N/A, N=255, Completed, University of Minnesota | Recruiting --> Completed | Trial completion date: Jun 2026 --> Apr 2024 | Trial primary completion date: Jun 2025 --> Apr 2024
    Trial completion • Trial completion date • Trial primary completion date
    16d
    ROSELLA: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (clinicaltrials.gov)
    P3, N=360, Active, not recruiting, Corcept Therapeutics | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    albumin-bound paclitaxel • relacorilant (CORT125134)
    17d
    Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Surgery
    |
    cisplatin • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    17d
    Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=22, Recruiting, University of Washington | Trial primary completion date: Apr 2024 --> Dec 2024 | Trial completion date: Apr 2025 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • carboplatin
    20d
    Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=10, Terminated, Pfizer | Active, not recruiting --> Terminated; A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study for administrative reasons. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.
    Trial termination • Combination therapy
    |
    pegylated liposomal doxorubicin • maplirpacept (TTI-622)
    21d
    Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=75, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CTAG1B (Cancer/testis antigen 1B)
    |
    PD-L1 expression • CTAG1B expression
    |
    Tecentriq (atezolizumab) • Hiltonol (poly-ICLC) • guadecitabine (SGI-110) • rasdegafusp alfa (CDX-1401)
    21d
    Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (clinicaltrials.gov)
    P1, N=21, Suspended, M.D. Anderson Cancer Center | N=36 --> 21 | Recruiting --> Suspended
    Enrollment change • Trial suspension • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cometriq (cabozantinib capsule)
    22d
    HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer (clinicaltrials.gov)
    P2, N=460, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GSK5733584
    23d
    Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=33, Not yet recruiting, Masonic Cancer Center, University of Minnesota
    New P1 trial
    |
    fludarabine IV
    23d
    A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
    P1/2, N=141, Active, not recruiting, 23andMe, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    23ME-00610
    23d
    MIRRORS: a prospective cohort study assessing the feasibility of robotic interval debulking surgery for advanced-stage ovarian cancer. (PubMed, Int J Gynecol Cancer)
    Robotic interval debulking surgery appears safe and feasible for experienced robotic surgeons in patients with a pelvic mass ≤8 cm. A randomized controlled trial (MIRRORS-RCT) will determine whether MIRRORS protocol has non-inferior survival (overall and progression-free) compared with open interval debulking surgery.
    Journal • Surgery • Metastases
    |
    BRCA (Breast cancer early onset)
    24d
    Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy (clinicaltrials.gov)
    P=N/A, N=22, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    28d
    Natural Killer Cell Dysfunction in Premenopausal BRCA1 Mutation Carriers: A Potential Mechanism for Ovarian Carcinogenesis. (PubMed, Cancers (Basel))
    Phase-specific differential NK cell activity in BRCA1 mutation carriers, either systemically or locally, may favor site-specific pre-invasive carcinogenesis. These cumulative effects across a reproductive lifecycle in high-risk carriers can have a detrimental effect further supporting epidemiological evidence for ovulation inhibition.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • NCAM1 (Neural cell adhesion molecule 1)
    |
    BRCA1 mutation
    |
    Mifeprex (mifepristone)
    1m
    A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov)
    P2/3, N=650, Recruiting, Daiichi Sankyo | Not yet recruiting --> Recruiting
    Enrollment open
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • raludotatug deruxtecan (DS-6000)
    1m
    Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer (clinicaltrials.gov)
    P3, N=50, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • capecitabine • oxaliplatin • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    1m
    "Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=3, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide
    1m
    Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis (clinicaltrials.gov)
    P1, N=26, Active, not recruiting, M.D. Anderson Cancer Center | N=48 --> 26
    Enrollment change • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    1m
    Journey Ahead: Enhancing Coping and Communication for Women Diagnosed With Gynecological Cancer (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, Rutgers, The State University of New Jersey | Trial primary completion date: Dec 2023 --> May 2024
    Trial primary completion date
    1m
    A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary (clinicaltrials.gov)
    P1/2, N=14, Active, not recruiting, Avenge Bio, Inc | Recruiting --> Active, not recruiting | N=44 --> 14
    Enrollment closed • Enrollment change
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    AVB-001
    1m
    R5668-ONC-1938: A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018 (clinicaltrials.gov)
    P1/2, N=612, Recruiting, Regeneron Pharmaceuticals | N=326 --> 612 | Trial primary completion date: Jan 2027 --> Apr 2027
    Enrollment change • Trial primary completion date • Combination therapy
    |
    Libtayo (cemiplimab-rwlc) • ubamatamab (REGN4018) • Kevzara (sarilumab) • REGN5668
    1m
    NCI-2018-01137: Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF (clinicaltrials.gov)
    P1, N=300, Recruiting, M.D. Anderson Cancer Center | N=120 --> 300 | Trial completion date: Jun 2025 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    BRCA (Breast cancer early onset)
    1m
    Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7) (clinicaltrials.gov)
    P3, N=376, Active, not recruiting, Mural Oncology, Inc | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Keytruda (pembrolizumab) • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • nemvaleukin alfa (ALKS 4230)
    1m
    Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Mario Negri Institute for Pharmacological Research | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Zejula (niraparib)
    1m
    Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, University of Washington | Initiation date: Apr 2024 --> Jan 2024
    Trial initiation date
    1m
    NCI-2018-01758: Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=4, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Jan 2024 --> Jan 2027
    Trial completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    melphalan • Proleukin (aldesleukin)
    1m
    Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Mayo Clinic | N=60 --> 100
    Enrollment change • Metastases
    1m
    Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery
    |
    IDO1 (Indoleamine 2,3-dioxygenase 1)
    |
    epacadostat (INCB024360)
    2ms
    Targeting tryptophan catabolism in ovarian cancer to attenuate macrophage infiltration and PD-L1 expression. (PubMed, Cancer Res Commun)
    The orally available dual IDO1/TDO2 inhibitor, AT-0174, significantly inhibited tumor progression, reduced tumor-associated macrophages, and reduced expression of immune-suppressive proteins on immune and tumor cells. These studies demonstrate the importance of TDO2 and the therapeutic potential of AT-0174 to overcome an immune-suppressed TME.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IL6 (Interleukin 6) • TDO2 (Tryptophan 2,3-Dioxygenase)
    |
    PD-L1 expression
    2ms
    NM32-2668 in Adult Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Numab Therapeutics AG
    New P1 trial • Trispecific • Metastases
    2ms
    Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. (PubMed, Gynecol Oncol)
    This triplet regimen (MIRV+carboplatin+bevacizumab) was highly active, with a tolerable AE profile in participants with recurrent, platinum-sensitive, FRα-expressing ovarian cancer. Thrombocytopenia was the primary cause of dose modifications. These outcomes compare favorably to historical data reported for platinum-based chemotherapy plus bevacizumab regimens in similar patient populations.
    P1 data • Journal • Combination therapy
    |
    FOLR1 ( Folate receptor alpha )
    |
    FOLR1 expression
    |
    Avastin (bevacizumab) • carboplatin • Elahere (mirvetuximab soravtansine-gynx)
    2ms
    Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=23, Active, not recruiting, Rhizen Pharmaceuticals SA | Trial primary completion date: Dec 2023 --> Mar 2024
    Trial primary completion date • Metastases
    |
    HRD (Homologous Recombination Deficiency)
    |
    RP12146